Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 7Lymphoid 4Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 143Leukemia 135Leukemia, Myeloid, Acute 117Lymphoma 83Burkitt Lymphoma 68Lymphoma, Non-Hodgkin 65Lymphoma, Large B-Cell, Diffuse 63Leukemia, Lymphocytic, Chronic, B-Cell 56Lymphoma, Follicular 55Lymphoma, Large-Cell, Immunoblastic 52Lymphoma, Mantle-Cell 49Congenital Abnormalities 43Lymphoma, B-Cell, Marginal Zone 42Myelodysplastic Syndromes 35Hodgkin Disease 35Leukemia, Myelomonocytic, Acute 32Leukemia, Monocytic, Acute 31Leukemia, Erythroblastic, Acute 31Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 29Leukemia, Megakaryoblastic, Acute 29Multiple Myeloma 25Blast Crisis 22Waldenstrom Macroglobulinemia 21Recurrence 21Myeloproliferative Disorders 21Leukemia, Myeloid, Chronic-Phase 20Leukemia, Myeloid, Accelerated Phase 20Dendritic Cell Sarcoma, Interdigitating 19Lymphoma, T-Cell, Cutaneous 18Leukemia, Myelomonocytic, Chronic 18

Interventions

Alemtuzumab 3Cyclophosphamide 2tocilizumab 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Methotrexate 1Melphalan 1Etoposide 1Dexamethasone 1Cytarabine 1Calcium Dobesilate 1Busulfan 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphohistiocytosis, Hemophagocytic × Etoposide × Other hematologic neoplasm × Clear all
NCT02385110 2024-01-17

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

M.D. Anderson Cancer Center

Phase 2 Completed
18 enrolled 10 charts
MyeloidOther hematologic neoplasm

Leukemia, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡